Enzyme-Prodrug Strategies for Cancer Therapy:
Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEP...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boston, MA
Springer US
1999
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail |
| Beschreibung: | 1 Online-Ressource (XIII, 257 p) |
| ISBN: | 9781461548232 |
| DOI: | 10.1007/978-1-4615-4823-2 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046146551 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1999 |||| o||u| ||||||eng d | ||
| 020 | |a 9781461548232 |9 978-1-4615-4823-2 | ||
| 024 | 7 | |a 10.1007/978-1-4615-4823-2 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4615-4823-2 | ||
| 035 | |a (OCoLC)1119116046 | ||
| 035 | |a (DE-599)BVBBV046146551 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616 |2 23 | |
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Enzyme-Prodrug Strategies for Cancer Therapy |c edited by Roger G. Melton, Richard J. Knox |
| 264 | 1 | |a Boston, MA |b Springer US |c 1999 | |
| 300 | |a 1 Online-Ressource (XIII, 257 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail | ||
| 650 | 4 | |a Internal Medicine | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Biochemistry, general | |
| 650 | 4 | |a Biomedical Engineering and Bioengineering | |
| 650 | 4 | |a Internal medicine | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Biochemistry | |
| 650 | 4 | |a Biomedical engineering | |
| 650 | 0 | 7 | |a Enzyminduktion |0 (DE-588)4332491-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pro-Pharmakon |0 (DE-588)4193853-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Zielorgan |0 (DE-588)4205824-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 1 | |a Pro-Pharmakon |0 (DE-588)4193853-7 |D s |
| 689 | 0 | 2 | |a Enzyminduktion |0 (DE-588)4332491-5 |D s |
| 689 | 0 | 3 | |a Zielorgan |0 (DE-588)4205824-7 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 1 | 2 | |a Pro-Pharmakon |0 (DE-588)4193853-7 |D s |
| 689 | 1 | |8 3\p |5 DE-604 | |
| 700 | 1 | |a Melton, Roger G. |4 edt | |
| 700 | 1 | |a Knox, Richard J. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461371861 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780306458958 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461548249 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4615-4823-2 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031526736 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-1-4615-4823-2 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180484676124672 |
|---|---|
| any_adam_object | |
| author2 | Melton, Roger G. Knox, Richard J. |
| author2_role | edt edt |
| author2_variant | r g m rg rgm r j k rj rjk |
| author_facet | Melton, Roger G. Knox, Richard J. |
| building | Verbundindex |
| bvnumber | BV046146551 |
| classification_rvk | XI 7000 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4615-4823-2 (OCoLC)1119116046 (DE-599)BVBBV046146551 |
| dewey-full | 616 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616 |
| dewey-search | 616 |
| dewey-sort | 3616 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-4615-4823-2 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03768nmm a2200745zc 4500</leader><controlfield tag="001">BV046146551</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1999 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461548232</subfield><subfield code="9">978-1-4615-4823-2</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4615-4823-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4615-4823-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119116046</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146551</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Enzyme-Prodrug Strategies for Cancer Therapy</subfield><subfield code="c">edited by Roger G. Melton, Richard J. Knox</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XIII, 257 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Internal Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biochemistry, general</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomedical Engineering and Bioengineering</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biochemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomedical engineering</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Enzyminduktion</subfield><subfield code="0">(DE-588)4332491-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pro-Pharmakon</subfield><subfield code="0">(DE-588)4193853-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Zielorgan</subfield><subfield code="0">(DE-588)4205824-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pro-Pharmakon</subfield><subfield code="0">(DE-588)4193853-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Enzyminduktion</subfield><subfield code="0">(DE-588)4332491-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Zielorgan</subfield><subfield code="0">(DE-588)4205824-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Pro-Pharmakon</subfield><subfield code="0">(DE-588)4193853-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melton, Roger G.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knox, Richard J.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461371861</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780306458958</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461548249</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4615-4823-2</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526736</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4615-4823-2</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046146551 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:30Z |
| institution | BVB |
| isbn | 9781461548232 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526736 |
| oclc_num | 1119116046 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XIII, 257 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1999 |
| publishDateSearch | 1999 |
| publishDateSort | 1999 |
| publisher | Springer US |
| record_format | marc |
| spelling | Enzyme-Prodrug Strategies for Cancer Therapy edited by Roger G. Melton, Richard J. Knox Boston, MA Springer US 1999 1 Online-Ressource (XIII, 257 p) txt rdacontent c rdamedia cr rdacarrier Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail Internal Medicine Oncology Immunology Biochemistry, general Biomedical Engineering and Bioengineering Internal medicine Oncology Biochemistry Biomedical engineering Enzyminduktion (DE-588)4332491-5 gnd rswk-swf Pro-Pharmakon (DE-588)4193853-7 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Zielorgan (DE-588)4205824-7 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Cytostatikum (DE-588)4068347-3 s Pro-Pharmakon (DE-588)4193853-7 s Enzyminduktion (DE-588)4332491-5 s Zielorgan (DE-588)4205824-7 s 2\p DE-604 Krebs Medizin (DE-588)4073781-0 s 3\p DE-604 Melton, Roger G. edt Knox, Richard J. edt Erscheint auch als Druck-Ausgabe 9781461371861 Erscheint auch als Druck-Ausgabe 9780306458958 Erscheint auch als Druck-Ausgabe 9781461548249 https://doi.org/10.1007/978-1-4615-4823-2 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Enzyme-Prodrug Strategies for Cancer Therapy Internal Medicine Oncology Immunology Biochemistry, general Biomedical Engineering and Bioengineering Internal medicine Oncology Biochemistry Biomedical engineering Enzyminduktion (DE-588)4332491-5 gnd Pro-Pharmakon (DE-588)4193853-7 gnd Krebs Medizin (DE-588)4073781-0 gnd Zielorgan (DE-588)4205824-7 gnd Cytostatikum (DE-588)4068347-3 gnd |
| subject_GND | (DE-588)4332491-5 (DE-588)4193853-7 (DE-588)4073781-0 (DE-588)4205824-7 (DE-588)4068347-3 (DE-588)4143413-4 |
| title | Enzyme-Prodrug Strategies for Cancer Therapy |
| title_auth | Enzyme-Prodrug Strategies for Cancer Therapy |
| title_exact_search | Enzyme-Prodrug Strategies for Cancer Therapy |
| title_full | Enzyme-Prodrug Strategies for Cancer Therapy edited by Roger G. Melton, Richard J. Knox |
| title_fullStr | Enzyme-Prodrug Strategies for Cancer Therapy edited by Roger G. Melton, Richard J. Knox |
| title_full_unstemmed | Enzyme-Prodrug Strategies for Cancer Therapy edited by Roger G. Melton, Richard J. Knox |
| title_short | Enzyme-Prodrug Strategies for Cancer Therapy |
| title_sort | enzyme prodrug strategies for cancer therapy |
| topic | Internal Medicine Oncology Immunology Biochemistry, general Biomedical Engineering and Bioengineering Internal medicine Oncology Biochemistry Biomedical engineering Enzyminduktion (DE-588)4332491-5 gnd Pro-Pharmakon (DE-588)4193853-7 gnd Krebs Medizin (DE-588)4073781-0 gnd Zielorgan (DE-588)4205824-7 gnd Cytostatikum (DE-588)4068347-3 gnd |
| topic_facet | Internal Medicine Oncology Immunology Biochemistry, general Biomedical Engineering and Bioengineering Internal medicine Oncology Biochemistry Biomedical engineering Enzyminduktion Pro-Pharmakon Krebs Medizin Zielorgan Cytostatikum Aufsatzsammlung |
| url | https://doi.org/10.1007/978-1-4615-4823-2 |
| work_keys_str_mv | AT meltonrogerg enzymeprodrugstrategiesforcancertherapy AT knoxrichardj enzymeprodrugstrategiesforcancertherapy |